ArticleChinese medicine2025
Deciphering the antiviral mechanisms of Fangqin Qinggan decoction against influenza A virus: a multi-omics and machine learning approach.
Article in Chinese medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- A visualization analysis of Traditional Chinese Medicine for influenza prevention and treatment: advances, hotspots, and future trends.Frontiers in medicine · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInfluenza A virus (IAV) infection poses a significant global health burden, contributing to high morbidity and mortality in both humans and animals through rapid viral transmission and dysregulated inflammatory responses. Fangqin Qinggan Decoction (FQ-01), a traditional Chinese medicine (TCM) formula, has demonstrated clinical efficacy in treating viral upper respiratory infections, however, its underlying therapeutic mechanisms remain poorly understood.
methodsThe therapeutic efficacy and mechanisms of FQ-01 against IAV infection were comprehensively investigated using a multidisciplinary approach, including in vivo murine models, histopathological (H&E staining), RT-qPCR, immunohistochemistry (IHC), network pharmacology, weighted gene co-expression network analysis (WGCNA), machine learning (LASSO), transcriptomics, metabolomics, molecular docking and molecular dynamics (MD) simulation.
resultsFQ-01 significantly improved survival rates, reduced clinical mortality, and mitigated pulmonary inflammation in an IAV-infected mice while suppressing viral replication. Integrated bioinformatics and LASSO regression analyses identified 20 genes associated with FQ-01's antiviral effects, with Myd88 and Ccl5 emerging as key targets. Transcriptomic profiling of murine lung tissues further validated these genes as critical mediators of FQ-01's therapeutic action. Spearman correlation analysis revealed strong associations between Myd88/Ccl5 expression and serum/lung metabolites, particularly 3-indolyl sulfate and inosine. Subsequent in vivo RT-qPCR and IHC validation, molecular docking, and MD simulations confirmed that FQ-01 exerts its anti-IAV effects by inhibiting Myd88 and Ccl5 expression.
conclusionsOur findings elucidate the molecular mechanisms underlying FQ-01's therapeutic potential against IAV infection, highlighting Myd88 and Ccl5 as promising targets for antiviral and anti-inflammatory interventions. This study provides a foundation for further exploration of TCM-based strategies in combating influenza and related respiratory infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.